CARLSBAD, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $2.6 million, or $0.42 per diluted share, on net sales of $34.8 million for the second quarter of fiscal year 2026 compared to a net loss of $2.2 million, or $0.37 per diluted share, in the second quarter of the prior fiscal year.
Net sales during the three months ended December 31, 2025, increased $0.7 million, or 2%, to $34.8 million as compared to $34.1 million recorded in the comparable prior year period. During the same period, private-label contract manufacturing sales increased 2% to $32.8 million. Private-label contract manufacturing sales increased primarily due to increased orders from several of our existing customers and shipments to new customers, partially offset by decreased shipments to other existing customers.
CarnoSyn$(R)$ beta-alanine royalty, licensing and raw material sales revenue increased 13% to $2.0 million during the second quarter of fiscal year 2026, as compared to $1.8 million for the second quarter of fiscal year 2025. The increase was primarily due to increased raw material orders from existing customers partially offset by a decrease in royalty and licensing revenue.
Our net loss for the six months ended December 31, 2025, was $2.8 million, or $0.47 per diluted share, compared to a net loss of $4.2 million, or $0.70 per diluted share, for the six months ended December 31, 2024.
Net sales during the six months ended December 31, 2025, increased $5.3 million, or 8%, to $72.5 million as compared to $67.2 million recorded in the comparable prior year period. During the six months ended December 31, 2025, private-label contract manufacturing sales increased 9% to $68.9 million, as compared to $62.9 million in the comparable prior period. CarnoSyn(R) beta-alanine royalty, licensing and raw material sales revenue decreased 15% to $3.7 million during the first six months of fiscal 2026, as compared to $4.3 million for the first six months of fiscal 2025.
While we grew our net sales, expanded our gross margins and reduced selling, general and administrative costs during the three and six months ended December 31, 2025, we experienced a loss from operations during the first six months of fiscal 2026 primarily due to underutilization of our factory capacities. The improvement in gross profit is primarily related to increased new and existing customer sales that also drove improved factory utilization. Although we anticipate we will increase our sales revenue during the remaining two quarters of fiscal 2026 as compared to the prior year periods and the first half of this year, we now believe that we will experience a net loss in the second half of fiscal 2026, and a net loss for the full fiscal 2026 year due to reductions in several of our customer's forecasted sales along with delayed new product launches.
As of December 31, 2025, we had cash of $3.8 million and working capital of $28.7 million, compared to $12.3 million and $30.5 million respectively, as of June 30, 2025. As of December 31, 2025, we had $10.0 million of borrowing capacity on our credit facility of which we had outstanding borrowings of $5.8 million.
Mark A. Le Doux, Chairman and Chief Executive Officer of NAI stated, "NAI is experiencing some disappointments in the ability to accurately forecast demand from several clients engaged in the multi-level marketing and direct selling channels of commerce, in China, Europe and in some cases North America. We believe that efforts are underway by our clients to rectify these challenges by introducing new products and reinvigorating their sales efforts in these various markets. Other sales channels of our business are growing, and we are seeing this as well in large retailer environments, warehouse stores and through internet-based sales direct to consumers.
While we assist our direct selling customer base with their sales and inventory modification efforts, we are also diligently managing our cost and expenses during this challenging environment. We continue to focus on the expansion of acceptance of our CarnoSyn(R) patent estate with the introduction of the highly bioavailable and beneficial form of beta-alanine in our patent pending TriBsyn$(TM)$ molecule which has demonstrated the capability of delivering 4 times the effectiveness of instant release beta-alanine with lower dosing and resulting absence of paresthesia. As the weight loss phenomenon attributed to utilization of GLP-1 and related metabolic indicators continues to grow, the opportunity to provide TriBsyn(TM) and SR CarnoSyn(R) to retard or prevent the onset of muscle wasting attributed to reduced caloric and protein intake of those utilizing GLP-1 medications is significant. This is also an essential compound for use in nutritional supplementation of the elderly to support age-based sarcopenia. We remain committed to expanding the adoption of this scientifically revolutionary molecule."
An updated investor presentation will be posted to the investor relations page on our website later today .
NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging, and delivery system design, regulatory review, and international product registration assistance. For more information about NAI, please see our website at http://www.nai-online.com.
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our ability to develop, maintain or increase sales to new and existing customers, and our future revenue, profits and financial condition. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks, including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.
SOURCE - Natural Alternatives International, Inc.
CONTACT -- Michael Fortin, Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or investor@nai-online.com.
Web site: http://www.nai-online.com
NATURAL ALTERNATIVES INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited) (Unaudited)
Three Months Ended Six Months Ended
December 31, December 31,
----------------------------------- -----------------------------------
2025 2024 2025 2024
------ ------ ------ ------
NET SALES $ 34,795 100.0% $ 34,078 100.0% $ 72,525 100.0% $ 67,228 100.0%
Cost of goods
sold 32,304 92.8% 32,409 95.1% 65,637 90.5% 63,300 94.2%
------ ----- ------ ----- ------ ----- ------ -----
Gross profit 2,491 7.2% 1,669 4.9% 6,888 9.5% 3,928 5.8%
Selling,
general &
administrative
expenses 4,338 12.5% 4,449 13.1% 8,451 11.7% 8,544 12.7%
------ ------ ------ ------
LOSS FROM
OPERATIONS (1,847) -5.3% (2,780) -8.2% (1,563) -2.2% (4,616) -6.9%
Other expense,
net (482) -1.4% (86) -0.3% (965) -1.3% (663) -1.0%
------ ----- ------ ----- ------ ----- ------ -----
LOSS BEFORE
TAXES (2,329) -6.7% (2,866) -8.4% (2,528) -3.5% (5,279) -7.9%
Income tax
provision
(benefit) 224 (675) 316 (1,106)
------ ------ ------ ------
NET LOSS $ (2,553) $ (2,191) $ (2,844) $ (4,173)
====== ====== ====== ======
NET LOSS PER
COMMON SHARE:
Basic: ($ 0.42) ($ 0.37) ($ 0.47) ($ 0.70)
====== ====== ====== ======
Diluted: ($ 0.42) ($ 0.37) ($ 0.47) ($ 0.70)
====== ====== ====== ======
WEIGHTED
AVERAGE COMMON
SHARES
OUTSTANDING:
(MORE TO FOLLOW) Dow Jones Newswires
February 13, 2026 16:30 ET (21:30 GMT)